FAQ

Translational medicine and its perspectives in Poland

Publication date: 24.10.2016

Public Health and Governance, 2016, Volume 14, Issue 2, pp. 93 - 103

https://doi.org/10.4467/20842627OZ.16.013.5575

Authors

,
Zuzanna Drożdzak
Jagiellonian University in Kraków, Gołębia 24, 31-007 Kraków, Poland
Małopolska Centre for Translational Medicine
All publications →
,
Patrycja Antosz
Jagiellonian University in Kraków, Gołębia 24, 31-007 Kraków, Poland
Małopolska Centre for Translational Medicine
All publications →
,
Jan Strycharz
Małopolska Centre for Translational Medicine
All publications →
,
Seweryn Krupnik
Małopolska Centre for Translational Medicine
All publications →
,
Anna Szczucka
Małopolska Centre for Translational Medicine
All publications →
,
Dariusz Szklarczyk
Fundacja Rozwoju Badań Społecznych
All publications →
Karolina Łukasiewicz
Małopolska Centre for Translational Medicine
All publications →

Titles

Translational medicine and its perspectives in Poland

Abstract

This article presents Translational Medicine (TM), one of today’s ‘buzz words’. Moreover, it seeks to identify the factors which stimulate or impede TM’s development in Poland, based on desk research and a series of expert interviews conducted in four countries. TM is a new trend in research and clinical practice. It stems from two sources: observation of how ineffective the traditional drug development process is, and from the public need for innovative therapies. Strategies developed within the translational approach optimize medical innovation development so that the chasm between impressive scientific discoveries and poor pharma productivity is filled. Our diagnosis shows that Poland is a minor player on the market of new technologies, particularly drugs. However, Polish scientists and industry do have a potential that will enable them to play major roles in international research teams that work on innovative, global projects.

References

Wehling M. (ed.), Principles of Translational Science in Medicine. From Bench to Bedside. Cambridge University Press, Cambridge, New York 2010.

Palmer A.M., Sundstrom L., Translational medicines research, “Drug Discov. Today” 2013; 18 (11–12): 503–505.

Jogalekar A., The perils of translational research. 2012, http://blogs.scientificamerican.com/the-curious-wavefunction/2012/11/26/the-perils-of-translational-research/; accessed: 20.07.2014.

Munos B., Lessons from 60 years of pharmaceutical innovation, “Nat. Rev. Drug Discov.” 2009; 8 (12): 959–968.

Riccaboni M., Is there productivity crisis in pharmaceutical R&D? Seminar briefing no. 11. 2012.

Lipiński P.F.J., Plewczyński D., Dziewięciu wspaniałych, Cz. I, “Przem. Farm.” 2012; 5: 40–44.

Pammolli F., Magazzini L., Riccaboni M., The productivity crisis in pharmaceutical R&D, “Nat. Rev. Drug Discov.” 2011; 10 (6): 428–438.

Pich E.M., Understanding pharmacology in humans: Phase and Phase II (Data Generation), “Curr. Opin. Pharmacol.” 2011; 11 (5): 557–562.

Tralau-Stewart C.J., Wyatt C.A., Kleyn D.E., Ayad A., Drug discovery: new models for industry – academic partnerships, “Drug Discov. Today” 2009; 14 (1–2): 95–101.

Adams D.J., The Valley of Death in anticancer drug development: reassessment, “Trends Pharmacol. Sci” 2013; 33 (4): 173–180.

Jones B.F., The burden of knowledge and the ‘Death of the Renaissance Man’: is innovation getting harder?, “Rev. Econ. Stat.” 2009; 76: 283–317.

Guzik T., Medycyna translacyjna – czyli laboratorium do łóżka chorego... i z powrotem, “Kosmos” 2010; 59 (1–2): 257–262.

Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L., How to improve R&D productivity: the pharmaceutical industry’s grand challenge, “Nat. Rev. Drug Discov.” Mar. 2010; 9 (3): 203–214.

West W., Nightingale P., Organizing for innovation: towards successful translational research, “Trends Biotechnol.” 2009; 27 (10): 558–561.

Sams-Dodd F., Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of paradigm shift, “Drug Discov. Today” 2013; 18 (5–6): 211–217.

Fishburn S., Translational research: the changing landscape of drug discovery, “Drug Discov. Today” 2013; (18) 9–10: 487–494.

Popytowe podejście do tworzenia innowacji – doświadczenia krajów skandynawskich, Polska Agencja Rozwoju Przedsiębiorczości, Warszawa 2012.

Milne C., Kaitin K.I., Translational medicine: an engine of community health, “Sci. Transl. Med.” 2009; 1 (5): 1–4.

Wizemann T., Robinson S., Giffin R., Current Model for Financing Drug Development: From Concept Through Approval, [in:] Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individual Therapies, The National Academic Press, Washington DC. 2008: 7–11.

Chesbrough H., Open Innovation: The New Imperative for Creating and Profiting from Technology, Harvard Business Press School, Boston 2003.

Ogilvie D., Craig P., Griffin S., Macintyre S., Wareham N.J., translational framework for public health research, “BMC Public Health” 2009; 9: 116.

Kardas P., Co medycyna translacyjna ma wspólnego codzienną pracą lekarza rodzinnego?, “Fam. Med. Prim. Care Rev.” 2011; 13 (2): 322–324.

Sympozjum „Badania translacyjne chorobach układu sercowo-naczyniowego”, 8 czerwca 2011 roku, Warszawa, https://www.ikard.pl/sympozjum-badania-translacyjne-w-chorobach-ukladu-sercowo-naczyniowego.html; accessed: 20.07.2014

“24 Zdrowie”, 2011, http://24zdrowie.pl/2011/06/100-naukowcow-o-medycynie-translacyjnej/; accessed: 20.07.2014

Inteligentne Specjalizacje Województwa Małopolskiego. Uszczegółowienie obszarów wskazanych Regionalnej Strategii Innowacji Województwa Małopolskiego 2014–2020, no. 1. Załącznik nr 1 do Uchwały nr 1262/15 Zarządu Województwa Małopolskiego dnia 22 września 2015 r., 2015: 1–101; accessed: 10.10.2016.

Raport grupy roboczej na rzecz innowacji opiece zdrowotnej 2010, 2010.

Fleming T.R., Research and reporting methods addressing missing data in clinical trials, “Ann. Intern. Med.” 2011; 154: 113–117.

Ignatiowicz A., Ostrowski M., Wiśniewski J., Deneka B., Wkład innowacyjnego przemysłu farmaceutycznego rozwój polskiej gospodarki, PwC, Warszawa 2011.

Naskalski J., List Prezesa Zarządu do Członków Kolegium Medycyny Laboratoryjnej Polsce. “Kolegium Medycyny Laboratoryjnej Polsce” 2012, http://www.kml.org.pl/index.php?option=com_content&view=article&id=67:xi-ty-ju-zjazd-kolegium-odbdzie-si-w-krakowie-w-dniach-17-19-stycznia-2013-r&catid=5:kml; accessed: 20.07.2014.

Graham P., Knowledge Transfer in Theory and Practice: Guide to the Literature, University of Saskatchewan, Saskatoon 2008.

Mittra J., Repairing the ‘Broken Middle’ of the health innovation pathway: exploring diverse practitioner perspectives on the emergence and role of translational medicine, “Sci. Technol. Stud.” 2013; 26 (3): 103–123.

Information

Information: Public Health and Governance, 2016, Volume 14, Issue 2, pp. 93 - 103

Article type: Original article

Titles:

Polish:

Translational medicine and its perspectives in Poland

English:

Translational medicine and its perspectives in Poland

Authors

Jagiellonian University in Kraków, Gołębia 24, 31-007 Kraków, Poland

Małopolska Centre for Translational Medicine

Jagiellonian University in Kraków, Gołębia 24, 31-007 Kraków, Poland

Małopolska Centre for Translational Medicine

Małopolska Centre for Translational Medicine

Małopolska Centre for Translational Medicine

Małopolska Centre for Translational Medicine

Fundacja Rozwoju Badań Społecznych

Małopolska Centre for Translational Medicine

Published at: 24.10.2016

Article status: Open

Licence: None

Percentage share of authors:

Zuzanna Drożdzak (Author) - 14%
Patrycja Antosz (Author) - 14%
Jan Strycharz (Author) - 14%
Seweryn Krupnik (Author) - 14%
Anna Szczucka (Author) - 14%
Dariusz Szklarczyk (Author) - 14%
Karolina Łukasiewicz (Author) - 16%

Article corrections:

-

Publication languages:

English

View count: 2213

Number of downloads: 1140

<p> Translational medicine and its perspectives in Poland</p>